Full Press Release Details
Ultragenyx Announces Crysvita (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting.
RARE
Ultragenyx Announces Crysvita (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Key Takeaway: Ultragenyx Announces Crysvita (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting
Price reaction · baseline $95.11 (2021-09-24 close) · clean, no other RARE news in the window
day 0 close
-6.8%
day 1 · peak
-8.5%
day 3
-5.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia